Home - Gastroenterology Advisor
Low-FODMAP and Gluten-Free Diets for IBS Improve Physical, Psychological Symptoms
Clinician Insights on How to Manage Semaglutide-Induced …
Sep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
Montelukast Fails to Reduce COVID-19 Symptom Duration in …
1 day ago · Treatment with montelukast is not associated with reduced symptom duration or shorter time to sustained recovery in adult outpatients with mild to moderate COVID-19 infection, according to study findings published in JAMA Network Open.. Researchers in the United States conducted a double-blinded, placebo-controlled randomized clinical trial (ClincalTrials.gov Identifier: NCT04885530) to ...
Assessment of Antispasmodics Available in North America for the ...
Data on the use of antispasmodics available in North America for the treatment of chronic abdominal pain in patients with disorders of gut-brain interaction (DGBI) vary dramatically in safety and efficacy, according to a literature review published in The American Journal of Gastroenterology.Overall, data supporting the use of antispasmodics in …
Bariatric Surgery for Weight Loss: Gastric Sleeve vs Gastric Bypass
Nov 1, 2024 · References: Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356. doi: 10.1016/j.soard.2022.08.013 American Society for Metabolic and Bariatric Surgery.
Gastroparesis Awareness Month: Updated Guidelines to Treat …
Aug 19, 2022 · The American College of Gastroenterology (ACG) released updated clinical guidelines on managing gastroparesis (GP). The new recommendations were published in The American Journal of Gastroenterology.. GP is characterized by delayed gastric emptying (GE) of solid food in the absence of mechanical obstruction.
What We Know About Semaglutide Adverse Events and …
Sep 1, 2023 · What Are Other Causes of Gastroparesis? Diabetes is the most common underlying cause of gastroparesis and can damage the vagus nerve, leading to impaired muscular function in the stomach and small intestine. 3 Studies show that the 10-year cumulative incidence of diabetic gastroparesis is estimated to be 5.2% among patients with type 1 diabetes and 1% in patients with type 2 diabetes. 4
FDA Alert: Gastroenterology Drug Approvals and New Indications
Sep 27, 2024 · Over the summer, the US Food and Drug Administration (FDA) approved a biosimilar for Crohn disease (CD) and ulcerative colitis (UC), a blood-based test for colorectal cancer (CRC) screening, a new indication for heartburn associated with nonerosive gastroesophageal reflux disease (GERD), a new indication for UC, and a new indication for younger patients with progressive familial intrahepatic ...
News and Features - Gastroenterology Advisor
The American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy Quality Task force have released updated guidance on quality indicators for colonoscopy.
Upper GI Tract Disorders Treated With P-CABs: AGA Clinical …
Oct 25, 2024 · The American Gastroenterological Association (AGA) has released a clinical practice update for managing upper gastrointestinal (GI) tract disorders with potassium-competitive acid blockers (P-CABs).